Belatacept
Title: Belatacept
CAS Registry Number: 706808-37-9
CAS Name: [29-Tyrosine,104-glutamic acid] CTLA-4 (antigen) (human extracellular domain-containing fragment) fusion protein with immunoglobulin G1 (human monoclonal Fc domain-containing fragment), bimol. (120®120¢)-disulfide
Additional Names: LEA29Y
Manufacturers' Codes: BMS-224818
Literature References: Selective costimulation blocker similar to abatacept, q.v. Soluble fusion protein combining a modified form of the extracellular portion of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) with the constant region of human IgG1. Prepn: R. J. Peach et al., WO 0192337; eidem US 05214313 (2001, 2005 both to Bristol-Myers Squibb). Pharmacology and development: C. P. Larsen et al., Am. J. Transpl. 5, 443 (2005). Clinical trial in rheumatoid arthritis: L. W. Moreland et al., Arthritis Rheum. 46, 1470 (2002); in renal transplantation: F. Vincenti et al., N. Engl. J. Med. 353, 770 (2005).
Therap-Cat: Immunosuppressant.
Keywords: Immunosuppressant.

Others monographs:
D-GalactoseAnistreplaseJatrorrhizineAcipimox
CitrullolIbufenacPyrethrum Flowersα-Furildioxime
Gallium ArsenideDihydroxytartaric AcidArogenic AcidTolbutamide
BudralazineEcabetFenoprofenEchinochrome A
©2016 DrugLead US FDA&EMEA